泰索帝联合顺铂治疗蒽环类药物耐药的晚期乳腺癌的临床研究

目的研究泰索帝联合顺铂治疗蒽环类药物耐药的晚期乳腺癌的疗效和安全性。方法28例蒽环类药物治疗失败的晚期乳腺癌患者均接受泰索帝联合顺铂方案治疗泰索帝75mg/m2静滴,第1天;顺铂80mg/m2静滴,第1天或分3天给予;每3周重复,完成3个周期化疗后评价疗效,有效病例4周后确认。结果28例患者均可评价疗效,CR3例,PR13例,SD11例,PD1例,总有效率(CR PR)57.1%(16/28)。主要不良反应为骨髓抑制。结论泰索帝联合顺铂是治疗蒽环类药物耐药的晚期乳腺癌的有效化疗方案,不良反应能够耐受。

The clinical study of docetaxel - cisplatin combination in treatment of anthracycline - resistant advanced breast cancer

Objective: To evaluate the efficacy and toxicity of combination chemotherapy with docetaxel and cisplatin in the treatment of anthracycline-resistant advanced breast cancer. Methods:Twenty eight patients with anthracycline-resistant advanced breast cancer were treated with docetaxel plus cisplatin, docetaxel was given at a dose of 75g/m2 on day 1 , cisplatin 80mg/m2 on day 1 or within 3 days,3 weeks was one circle, with at least three circles. The effective cases were confirmed after 4 weeks. Results: All 28 patients were evaluated for response.There were 3 complete response (CR), 13 partial response (PR), 11 stable disease (SD) and 1 progress disease (PD). The overall response rate (RR) was 57.1%. The major toxicity were myelosuppression. Conclusion: Combination chemotherapy with docetaxel and cisplatin is an effective method to treat anthracycline-resistant advanced breast cancer, and toxicities are tolerate.